Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin informs us about the World Health Organization research and development plan to combat endemic pathogens including hepatitis C virus, RSV and dengue virus, another case of mpox in Britian, the Marburg virus outbreak in Rwanda, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, if there is a benefit to additional COVID vaccinations after the initial series, ISDA guideline for using anti-SARS-CoV-2 monoclonal antibody therapy for prophylaxis, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, if and how do severe secondary bacterial infections develop following SARS-CoV-2 infection, and if COVID-19 associates with a risk of autoimmune and autoinflammatory connective tissue disorders.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Is the WHO the world’s NIH: endemic pathogens initiative (eBioMedicine)
• Another two cases of mpox in Britian (Reuters)
• How to stop Marburg virus (Rwanda Biomedical Centre)
• Marburg Virus fact sheet (Rwanda Biomedical Centre)
• Influenza weekly surveillance report: cliff notes (CDC FluView)
• RSV NETwork (CDC RSV)
• Respiratory virus activity (CDC Respiratory Illnesses)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Symptom reduction after additional vaccine dose during Omicron (OFID)
• IDSA Guideline update for SARS-CoV-2 monoclonal antibody pemivibart pre-exposure prophylaxis (CID)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• Fusion center near you….if in NY (Prime Fusions)